Difference between revisions of "Alvocidib (Flavopiridol)"
Jump to navigation
Jump to search
m (→Also known as) |
Warner-admin (talk | contribs) m (Text replacement - "'''dosing details in manuscript have been reviewed'''" to "'''dosing details in manuscript have been reviewed by our editors'''") |
||
(12 intermediate revisions by 2 users not shown) | |||
Line 6: | Line 6: | ||
===[[Acute myeloid leukemia]]=== | ===[[Acute myeloid leukemia]]=== | ||
==FLAM {{#subobject:8a86fb|Regimen=1}}== | ==FLAM {{#subobject:8a86fb|Regimen=1}}== | ||
− | + | ||
− | |||
− | |||
− | |||
FLAM: '''<u>FL</u>'''avopiridol (Alvocidib), '''<u>A</u>'''ra-C (Cytarabine), '''<u>M</u>'''itoxantrone | FLAM: '''<u>FL</u>'''avopiridol (Alvocidib), '''<u>A</u>'''ra-C (Cytarabine), '''<u>M</u>'''itoxantrone | ||
===Regimen {{#subobject:5340f1|Variant=1}}=== | ===Regimen {{#subobject:5340f1|Variant=1}}=== | ||
− | {| class="wikitable" style="width: 100%; text-align:center;" | + | {| class="wikitable sortable" style="width: 100%; text-align:center;" |
!style="width: 25%"|Study | !style="width: 25%"|Study | ||
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | !style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
Line 19: | Line 16: | ||
|- | |- | ||
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4800702/ Zeidner et al. 2015 (JHOC-J1101)] | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4800702/ Zeidner et al. 2015 (JHOC-J1101)] | ||
− | | style="background-color:#1a9851" |Randomized Phase | + | | style="background-color:#1a9851" |Randomized Phase 2 (E) |
|[[#Cytarabine_.26_Daunorubicin|7+3d, high-dose dauno]] | |[[#Cytarabine_.26_Daunorubicin|7+3d, high-dose dauno]] | ||
| style="background-color:#1a9850" |Superior CR rate | | style="background-color:#1a9850" |Superior CR rate | ||
Line 32: | Line 29: | ||
===References=== | ===References=== | ||
− | # '''JHOC-J1101:''' Zeidner JF, Foster MC, Blackford AL, Litzow MR, Morris LE, Strickland SA, Lancet JE, Bose P, Levy MY, Tibes R, Gojo I, Gocke CD, Rosner GL, Little RF, Wright JJ, Doyle LA, Smith BD, Karp JE. Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia. Haematologica. 2015 Sep;100(9):1172-9. Epub 2015 May 28. [ | + | # '''JHOC-J1101:''' Zeidner JF, Foster MC, Blackford AL, Litzow MR, Morris LE, Strickland SA, Lancet JE, Bose P, Levy MY, Tibes R, Gojo I, Gocke CD, Rosner GL, Little RF, Wright JJ, Doyle LA, Smith BD, Karp JE. Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia. Haematologica. 2015 Sep;100(9):1172-9. Epub 2015 May 28. [https://doi.org/10.3324/haematol.2015.125849 link to original article] '''dosing details in manuscript have been reviewed by our editors''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4800702/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/26022709/ PubMed] [https://clinicaltrials.gov/study/NCT01349972 NCT01349972] |
===[[Chronic lymphocytic leukemia]]=== | ===[[Chronic lymphocytic leukemia]]=== | ||
− | |||
− | |||
− | |||
− | |||
==Also known as== | ==Also known as== | ||
*'''Generic name:''' flavopiridol | *'''Generic name:''' flavopiridol | ||
− | *'''Code names:''' HMR 1275, L-868275 | + | *'''Code names:''' HMR-1275, L-868275 |
[[Category:Drugs]] | [[Category:Drugs]] | ||
[[Category:Oral medications]] | [[Category:Oral medications]] | ||
− | |||
− | |||
[[Category:CDK inhibitors]] | [[Category:CDK inhibitors]] | ||
− | [[Category: | + | [[Category:Acute myeloid leukemia medications (investigational)]] |
+ | [[Category:Chronic lymphocytic leukemia medications (investigational)]] | ||
[[Category:Investigational drugs]] | [[Category:Investigational drugs]] |
Latest revision as of 12:24, 15 July 2024
Mechanism of action
From the NCI Drug Dictionary: A synthetic N-methylpiperidinyl chlorophenyl flavone compound. As an inhibitor of cyclin-dependent kinase, alvocidib induces cell cycle arrest by preventing phosphorylation of cyclin-dependent kinases (CDKs) and by down-regulating cyclin D1 and D3 expression, resulting in G1 cell cycle arrest and apoptosis.
Route: PO
Preliminary data
Acute myeloid leukemia
FLAM
FLAM: FLavopiridol (Alvocidib), Ara-C (Cytarabine), Mitoxantrone
Regimen
Study | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|
Zeidner et al. 2015 (JHOC-J1101) | Randomized Phase 2 (E) | 7+3d, high-dose dauno | Superior CR rate |
Chemotherapy
- Alvocidib (Flavopiridol) 50 mg/m2 IV once per day on days 1 to 3
- Cytarabine (Ara-C) 667 mg/m2/day IV continuous infusion on days 6 to 8 (total dose: 2000 mg/m2)
- Mitoxantrone (Novantrone) 40 mg/m2 IV once on day 9
One course
References
- JHOC-J1101: Zeidner JF, Foster MC, Blackford AL, Litzow MR, Morris LE, Strickland SA, Lancet JE, Bose P, Levy MY, Tibes R, Gojo I, Gocke CD, Rosner GL, Little RF, Wright JJ, Doyle LA, Smith BD, Karp JE. Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia. Haematologica. 2015 Sep;100(9):1172-9. Epub 2015 May 28. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article PubMed NCT01349972
Chronic lymphocytic leukemia
Also known as
- Generic name: flavopiridol
- Code names: HMR-1275, L-868275